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The Charlie Gard case [1] generated immense media interest, but more importantly has bequeathed a 
valuable lesson to doctors and nurses around the world. 
 
Firstly, it reminds us that doctors should never propose any therapy or drug if they have not examined the 
patient and are not familiar with all the medical documents. This essential factor cannot be overlooked, no 
matter how expert the doctor wanting to participate in  the  patient’s  care may be. This becomes even more 
relevant when discussing new treatments to be considered for compassionate use in a particular patient, 
before the drug has undergone the rigorous preclinical and clinical testing required by law.  
Violating this principle can lead to confusion and creates false expectations in patients and families, but, 
importantly, also in others suffering from the same disease. In medicine, insufficient professional rigour and 
accountability can engender unnecessary pain and suffering for those concerned.  
Secondly, the case has reminded us that medicine, and specifically, high quality clinical care, must respect 
the confidentiality of the patient and the family, which means maintaining long periods of silence even in 
the face of international media clamour for information.  
Thirdly, palliative care represents the best treatment strategy in cases of incurable illness in children. 
 
As paediatric intensivists, anaesthesiologists and paediatricians involved in the care of terminally ill 
children, we would like to express our appreciation of how Great Ormond Street Hospital staff approached 
difficult decisions and utilized appropriate communication channels. The paediatric ICU staff gave 
prominence to the delicate and silent job of taking care of critically ill children [2]; they pointed out that it 
could be a difficult and painful task requiring them to attempt always to make the right (or rather, less 
wrong) choice, including the possibility of being misunderstood and targeted with sometimes ill-informed 
criticism.  
 
Paediatric health care is practised with the goal of promoting the best interests of the child. In some cases, 
on a thorough assessment of benefits and costs to the child, deciding to forgo life-sustaining medical 
treatment is the only ethically justifiable and appropriate option. Many scientific societies have supported 
this opinion. The Italian Society of Neonatal and Pediatric Anesthesia and Intensive Care recommends that 
“the availability of a diagnostic or therapeutic tool does not in itself impose the obligation to use it. The use 
of a diagnostic or therapeutic tool must comply with a criterion of proportionality, even in intensive care. 
(…)  The decision to limit, withdraw or withhold life-sustaining treatments considered disproportionate, thus 
allowing the evolution of the illness to take its natural course towards death  (…) represents a clinically and 
ethically correct choice”  [3].  The  very  recent  guidelines  of  American  Academy  of  Pediatrics  fully  support  this  
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 3 
approach and they also state: “It may be ethically supportable to forgo life sustaining medical treatment 
without family agreement in rare circumstances of extreme burden of treatment with no benefit to the 
patient beyond postponement of death” [4]. 




End of life decisions, withdrawing of life supports, withholding of life supports, Paediatric Intensive Care 
Unit, clinical ethics, palliative care. 
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